Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1143-1155

  Hedvat, Michael ^a,b   Emdad, Luni ^b   Das, Swadesh K ^b   Kim, Keetae ^b   Dasgupta, Santanu ^b   Thomas, Shibu ^b   Hu, Bin ^b   Zhu, Shan ^b   Dash, Rupesh ^b,e   Quinn, Bridget A ^b   Oyesanya, Regina A ^b   Kegelman, Timothy P ^b   Sokhi, Upneet K ^b   Sarkar, Siddik ^b   Erdogan, Eda ^b   Menezes, Mitchell E ^b   Bhoopathi, Praveen ^b   Wang, Xiang Yang ^b,c   Pomper, Martin G ^d   Wei, Jun ^a   Wu, Bainan ^a   Stebbins, John L ^a   Diaz, Paul W ^a   Reed, John C ^a   Pellecchia, Maurizio ^a   Sarkar, Devanand ^b,c   Fisher, Paul B ^a,b,c   more..

^a BURNHAM INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

AP 1; Apogossypol; BI 97C1; c fos; c jun; Cancer Terminator Virus; E1AF; ETV4; Gossypol; PEA3; Progression Elevated Gene 3; Sabutoclax

Indexed keywords

GOSSYPOL; GOSSYPOL DERIVATIVE; GREEN FLUORESCENT PROTEIN; METALLOPROTEINASE; PROTEIN BCL X; TRANSCRIPTION FACTOR PEA3;

ARTICLE; AUTOPSY; DISEASE COURSE; DRUG DESIGN; GENE THERAPY; HIGH THROUGHPUT SCREENING; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROMOTER REGION; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR VOLUME;

EID: 84872250115     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529709     Document Type: Article

References (86)

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
2. Dash, R.; Azab, B.; Shen, X.N.; Sokhi, U.K.; Sarkar, S.; Su, Z.Z.; Wang, X.Y., Claudio, P.P.; Dent, P.; Dmitriev, I.P.; Curiel, D.T.; Grant, S.; Sarkar, D.; Fisher, P.B. Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discovery Med., 2011, 11(56), 46-56.
3. Das, S.K.; Bhutia, S.K.; Kegelman, T.P.; Peachy L.; Oyesanya R.A.; Dasgupta S.; Sokhi, U.K.; Azab B.; Dash R.; Quinn B.A.; Kim K.; Barral P.M.; Su ZZ.; Boukerche H.; Sarkar, D.; Fisher P.B. MDA-9/syntenin: a positive gatekeeper of melanoma metastasis. Front. Biosci., 2012, 17, 1-15.
4. Reed, J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol., 1999, 17(9), 2941-53.
5. Johnstone, R.W.; Ruefli, A.A.; Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 2002, 108(2), 153-64.
6. Reed, J.C. Apoptosis-based therapies. Nat. Rev. Drug. Discov., 2002, 1(2), 111-21.
7. Reed, J.C. Bcl-2 family proteins. Oncogene, 1998, 17(25), 3225-36.
8. Reed, J.C. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv. Pharmacol., 1997, 41, 501-32.
9. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell. Biol., 2001, 3(2), 173-82.
10. Wang, J.L.; Liu, D.; Zhang, Z.J.; Shan, S.; Han, X.; Srinivasula, S.M.; Croce, C.M.; Alnemri, E.S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A., 2000, 97(13), 7124-9.
11. Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J.C.; Pellecchia, M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem., 2003, 46(20), 4259-64.
12. Wu, D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs, 1989, 38(3), 333-341. 13. Gilbert, N.E.; O'Reilly, J.E.; Chang, C.J.; Lin, Y.C.; Brueggemeier, R.W. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life. Sci., 1995, 57(1), 61-67.
13. Gilbert, N.E.; O'Reilly, J.E.; Chang, C.J.; Lin, Y.C.; Brueggemeier, R.W. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life. Sci., 1995, 57(1), 61-67
14. Wu, Y.W.; Chik, C.L.; Knazek, R.A. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res., 1989, 49(14), 3754-8.
15. Thomas, M.; von Hagen, V.; Moustafa, Y.; Montmasson, M.P.; Monet J.D. Effects of gossypol on the cell cycle phases in T-47D human breast cancer cells. Anticancer Res., 1991, 11(4), 1469-75.
16. Le Blanc, M.; Russo, J.; Kudelka, A.P.; Smith, J.A. An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol. Res., 2002, 46(6), 551-5.
17. Wang, X.; Wang, J.; Wong, S.C.; Chow, L.S.; Nicholls, J.M.; Wong, Y.C.; Liu, Y.; Kwong, D.L.; Sham, J.S.; Tsa, S.W. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci., 2000, 67(22), 2663-71.
18. Abou-Karam, M.;; Shier, W.T. Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall. Phytother. Res., 1999, 13(4), 337-40.
19. Fung, K.P.; Wu, T.W.; Lui, C.P. Purpurogallin inhibits DNA synthesis of murine fibrosarcoma L-929 and human U-87 MG glioblastoma cells in vitro. Chemotherapy, 1996, 42(3), 199-205.
20. Becattini, B.; Kitada, S.; Leone, M.; Monosov. E.; Chandler, S.; Zhai, D.; Kipps, T.J.; Reed, J.C.; Pellecchia, M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem. Biol., 2004, 11(3), 389-95.
21. Wei, J.; Stebbins, J.L.; Kitada, S.; Dash, R.; Zhai, D.; Placzek, W.; Wu, B.; Rega, M.F.; Zhang, Z.; Barile, E.; Yang, L.; Dahl, R.; Fisher, P.B.; Reed, J.C.; Pellecchia, M. An optically pure Apogossypolone derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. Frontiers. Oncology, 2012. in press.
22. Jia, L.; Coward, L.C.; Kerstner-Wood, C.D.; Cork, R.L.; Gorman, G.S.; Noker, P.E.; Kitada, S.; Pellecchia, M.; Reed, J.C. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother. Pharmacol., 2008, 61(1), 63-73.
23. Kitada, S.; Kress, C.L.; Krajewska, M.; Jia, L.; Pellecchia, M.; Reed, J.C. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood, 2008, 111(6), 3211-9.
24. Wei, J.; Kitada, S.; Rega, M.F.; Stebbins, J.L.; Zhai, D.; Cellitti, J.; Yuan, H.; Emdadi, A.; Dahl R.; Zhang, Z.; Yang, L.; Reed, J.C.; Pellecchia, M. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J. Med. Chem., 2009, 52(14), 4511-23.
25. Dash, R.; Azab, B.; Quinn, B.A.; Shen X.; Wang, X.Y.; Das, S.K.; Rahmani, M. J.; Wei, M.; P. Dent, Hedvat.; Dmitriev, I.P.; Curiel, D.T.; Grant, S.; Wu, B.; Stebbins, J.L.; Pellecchia, M.; Reed, J.C.; Sarkar, D.; Fisher, P.B. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc. Natl. Acad. Sci. U.S.A., 2011, 108(21), 8785-90.
26. Quinn, B.A.; Dash, R.; Azab, B.; Sarkar, S.; Das, S.K.; Kumar, S.; Oyesanya, R.A.; Dasgupta, S.; Dent, P.; Grant, S.; Rahmani, M.; Curiel, D.T.; Dmitriev, I.; Hedvat, M.; Wei, J.; Wu, B.; Stebbins, J.L.; Reed, J.C.; Pellecchia, M.; Sarkar, D.; Fisher, P.B. Targeting Mcl-1 for the therapy of cancer. Expert Opin. Invest. Drug, 2011, 20(10), 1397-411.
27. Babiss, L.E.; Zimmer, S.G.; Fisher, P.B. Reversibility of progression of the transformed phenotype in Ad5-transformed rat embryo cells. Science, 1985, 228(4703), 1099-101.
28. Fisher, P.B.; Bozzone, J.H.; Weinstein, I.B. Tumor promoters and epidermal growth factor stimulate anchorage-independent growth of adenovirus-tranformed rat embryo cells. Cell, 1979, 18(3), 695-705.
29. Su, Z.Z.; Goldstein, N.I.; H. Jiang.; Wang, M.N.; Duigou, G.J.; Young, C.S.; Fisher, P.B. PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis. Proc. Natl. Acad. Sci. U.S.A., 1999, 96(26), 15115-20.
30. Su, Z.Z.; Shi, Y.; Fisher, P.B. Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proc. Natl. Acad. Sci. U.S.A., 1997, 94(17), 9125-30.
31. Su, Z.Z.; Emdad, L.; Sarkar, D.; Randolph, A.; Valerie, K.; Yacoub, A.; Dent, P.; Fisher, P.B. Potential molecular mechanism for rodent tumorigenesis: mutational generation of Progression Elevated Gene-3 (PEG-3). Oncogene, 2005, 24(13), 2247-55.
32. Su, Z.Z.; Sarkar, D.; Emdad, L.; Duigou, G.J.; Young, C.S.; Ware, J.; Randolph, A.; Valerie, K.; Fisher, P.B. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc. Natl. Acad. Sci. U.S.A., 2005, 102(4), 1059-64.
33. Sarkar, D.; Su, Z.Z.; Vozhilla, N.; Park, E.S.; Gupta, P.; Fisher, P.B. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc. Natl. Acad. Sci. U.S.A., 2005, 102(39), 14034-9.
34. Sarkar, D.; Su, Z.Z.; Vozhilla, N.; Park, E.S.; Randolph, A.; Valerie, K.; Fisher, P.B. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res., 2005, 65(19), 9056-63.
35. Sarkar, D.; Lebedeva, I.V.; Su, Z.Z.; Park, E.S.; Chatman, L.; Vozhilla, N.; Dent, P.; Curiel, D.T.; Fisher, P.B. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res., 2007, 67(11), 5434-42.
36. Sarkar, D.; Su, Z.Z.; Park, E.S.; Vozhilla, N.; Dent, P.; Curiel, D.T.; Fisher, P.B. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene. Ther., 2008, 15(5), 293-302.
37. Bhang, H.E.; Gabrielson, K.L.; Laterra, J.; Fisher, P.B.; Pomper, M.G. Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat. Med., 2011, 17(1), 123-9.
38. Su, Z.Z.; Shi Y.; Fisher, P.B. Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene, 2000, 19(30), 3411-21.
39. Launoit, de.Y., Baert, J.L.; Chotteau-Lelievre, A.; Monte, D.; Coutte, L.; Mauen, S.; Firlej, V.; Degerny, C.; Verreman, K. The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim. Biophys. Acta., 2006, 1766(1), 79-87.
40. Higashino, F.; Yoshida, K.; Noumi, T.; Seiki, M.; Fujinaga, K. Etsrelated protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene, 1995, 10(7), 1461-3.
41. Hess, J.; Angel P.; Schorpp-Kistner, M. AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci., 2004, 117(Pt 25), 5965-73.
42. Shaulian, E.; Karin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol., 2002, 4(5), E131-6.
43. Wagner, E.F.; Eferl, R. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev., 2005, 208, 126-40.
44. Kang, D.C.; Motwani, M.; Fisher, P.B. Role of the transcription factor AP1 in melanoma differentiation. (review). Intl. J. Oncology, 1998, 13(6), 1117-26.
45. Vojtek, A.B.; Der, C.J. Increasing complexity of the Ras signaling pathway. J. Biol. Chem., 1998, 273(32), 19925-8.
46. O'Hagan, R.C.; Tozer, R.G.; Symons, M.; McCormick, F.; Hassell, J.A. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene, 1996, 13(6), 1323-33.
47. Hakuma, N.; Kinoshita, I.; Shimizu, Y.; Yamazaki, K.; Yoshida, K.; Nishimura, M.; Dosaka-Akita, H. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Cancer Res., 2005, 65(23), 10776-82.
48. Clementz, A.G.; Rogowski, A.; Pandya, K.; Miele, L.; Osipo, C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res. 2011, 13(3), R63.
49. Subbaramaiah, K.; Norton, L.; Gerald, W.; Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem., 2002, 277(21), 18649-57.
50. Gavrilov, D.; Kenzior, O.; Evans, M.; Calaluce, R.; Folk, W.R. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur. J. Cancer, 2001, 37(8), 1033-40.
51. Iguchi, A.; Kitajima, I.; Yamakuchi, M.; Ueno, S.; Aikou, T.; Kubo, T.; Matsushima, K.; Mukaida, N.; Maruyama, I. PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells. Biochem. Biophys. Res. Commun., 2000, 279(1), 166-71.
52. Kishimoto, H., Kojima, T.; Watanabe, Y.; Kagawa, S.; Fujiwara, T.; Uno, F.; Teraishi, F.; Kyo, S.; Mizuguchi, H.; Hashimoto, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat. Med., 2006, 12(10), 1213-9.
53. Ray, S.; Paulmurugan, R.; Patel M.R.; Ahn, B.C.; Wu L.; Carey, M.; Gambhir, S.S. Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol. Ther., 2008, 16(11), 1848-56.
54. Qiao, J.; Doubrovin M.; Sauter, B.V.; Huang, Y.; Guo, Z.S.; Balatoni, J.; Akhurst, T.; Blasberg, R.G.; Tjuvajev, J.G.; Chen, S.H.; Woo, S.L. Tumor-specific transcriptional targeting of suicide gene therapy. Gene. Ther., 2002, 9(3), 168-75.
55. Hingtgen, S.; Kasmieh, R.; Elbayly, E.; Nesterenko, I.; Figueiredo, J. L.; Dash, R.; Sarkar D.; Hall D.; Kozakov, D.; Vajda, S.; Fisher, P.B.; Shah, K. A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy. PLoS. One., 2012. in press.
56. Jiang, H.; Lin, J.J.; Su, Z.Z.; Goldstein, N.I.; Fisher, P.B. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995, 11(12), 2477-86.
57. Jiang, H.; Su, Z.-Z.; Lin, J.J.; Goldstein, N.I.; Young, C.S.H.; Fisher, P.B. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc. Natl. Acad. Sci. U.S.A., 1996, 93(17), 9160-5.
58. Su, Z.-Z.; Madireddi, M.T.; Lin, J.J.; Young, C.S.H.; Kitada, S.; Reed, J.C.; Goldstein N.I.; Fisher, P.B. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(24), 14400-5.
59. Lebedeva, I.V.; Su, Z.-Z.; Chang, Y.; Kitada, S.; Reed, J.C.; Fisher P.B. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene, 2002, 21(5), 708-18.
60. Sauane, M.; Gopalkrishnan, R.V.; Sarkar, D.; Su, Z.-Z.; Lebedeva, I.V.; Dent, P.; Pestka, S.; Fisher, P.B. Mda-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev., 2003, 14(1), 35-51.
61. Lebedeva, I.V.; Su, Z.-Z.; Sarkar, D.; Kitada, S.; Dent, P.; Waxman, S.; Reed, J.C.; Fisher, P.B. Melanoma differentiation associated gene-7, mda-7/IL-24, promotes apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res., 2003, 63(23), 8138-44.
62. Fisher, P.B. Is mda-7/IL-24 a 'magic bullet' for cancer? Cancer Res., 2005, 65(22), 10128-38.
63. Gupta, P.; Su, Z.-Z.; Lebedeva, I.V.; Sarkar, D.; Sauane, M.; Emdad, L.; Bachelor, M.A.; Grant, S.; Curiel, D.T.; Dent, P.; Fisher, P.B. mda-7/IL-24: Multifunctional cancer-specific apoptosisinducing cytokine. Pharmacol. Ther., 2006, 111(3), 596-628.
64. Gupta, P.; Walter, M.R.; Su, Z.-Z.; Lebedeva, I.V.; Emdad, L.; Randolph, A.; Valerie, K.; Sarkar, D.; Fisher, P.B. BiP/GRP78 is an intracellular target for mda-7/IL-24 induction of cancer-specific apoptosis. Cancer Res., 2006, 66(16), 8182-91.
65. Sarkar, D.; Lebedeva, I.V.; Gupta, P.; Emdad, L.; Sauane, M.; Dent, P.; Curiel, D.T.; Fisher, P.B. Melanoma differentiation associated gene-7 (mda-7)/IL-24: a "magic bullet" for cancer therapy? Expert. Opin. Biol. Ther., 2007, 7(5), 577-86.
66. Yacoub, A.; Park, M.A.; Gupta, P.; Rahmani, M.; Zhang, G.; Hamed, H.; Hanna, D.; Sarkar, D.; Lebedeva, I.V.; Emdad, L.; Sauane, M.; Vozhilla, N.; Spiegel, S.; Koumenis, C.; Graf, M.; Curiel, D.T.; Grant, S.; Fisher, P.B.; Dent, P. Caspase-, cathepsinand PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol. Cancer. Ther., 2008, 7(2), 297-313.
67. Sauane, M.; Su, Z.-Z.; Gupta, P.; Lebedeva, I.V.; Dent, P.; Sarkar, D.; Fisher, P.B. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc. Natl. Acad. Sci. U.S.A., 2008, 105(28), 9763-8.
68. Gao, P.; Sun, X.; Chen, X.; Wang, Y.; Foster, B.A.; Subjeck, J.; Fisher, P.B.; Wang, X.Y. Secretable chaperone Grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/IL-24. Cancer Res, 2008, 68(10), 3890-8.
69. Emdad, L.; Lebedeva, I.V.; Su, Z.-Z.; Gupta, P.; Sauane, M.; Dash, R.; Grant, S.; Dent, P.; Curiel, D.T.; Sarkar, D.; Fisher P.B. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer. Biol. Ther., 2009, 8(5), 391-400.
70. Dash, R.; Bhutia, S.K.; Azab, B.; Su, Z.-Z.; Quinn, B.A.; Kegelmen, T.P.; Das, S.K.; Kim, K.; Lee, S.-G.; Park, M.A.; Yacoub, A.; Rahmani, M.; Emdad, L.; Dmitriev, I.P.; Wang X.-Y.; Sarkar D.; Grant, S.; Dent, P.; Curiel, D.T., Fisher P.B. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancerspecific toxicity. Cytokine & Growth Factor Rev., 2010, 21(5), 381-91.
71. Dent, P.; Yacoub, A.; Hamed, H.A.; Park, M.A.; Dash, R.; Bhutia, S.K.; Sarkar, D.; Gupta, P.; Emdad, L.; Lebedeva, I.V.; Sauane, M.; Su, Z.-Z.; Rahmani, M.; Broaddus, W.C.; Young, H.F.; Lesniak, M.; Grant, S.; Fisher P.B. MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs, 2010, 21(8), 725-31.
72. Fisher, P.B.; Gopalkrishnan, R.V.; Chada, S.; Ramesh, R.; Grimm, E.A.; Rosenfeld, M.R.; Curiel, D.T.; Dent, P. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer. Biol. Ther., 2003, 2(4 Suppl 1), S23-37.
73. Cunningham, C.C.; Chada, S.; Merritt, J.A.; Ton, A.; Senzer, N.; Zhang, Y.; Mhashilkar, A.; Parker, K.; Vukelja, S.; Richards, D.; Hood, J.; Coffee, K.; Nemunaitis J. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol. Ther., 2005, 11(1), 149-59.
74. Tong, A.W.; Nemunaitis, J.; Su, D.; Zhang, Y.; Cunningham, C.; Senzer, N.; Netto, G.; Rich, D.; Mhashilkar, A.; Parker, K.; Coffee, K.; Ramesh, R.; Ekmekcioglu, S.; Grimm, E.A.; van Wart Hood J.; Merritt, J.; Chada, S. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanomadifferentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol. Ther., 2005, 11(1), 160-72.
75. Fisher, P.B.; Sarkar, D.; Lebedeva, I.V.; Emdad, L.; Gupta, P.; Sauane, M.; Su, Z.-Z.; Grant S.; Dent, P.; Curiel, D.T.; Senzer, N.; Nemunaitis, J. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol. Appl. Pharmacol., 2007, 224(3), 300-7.
76. Lebedeva, I.V.; Emdad, L.; Su, Z.-Z.; Gupta, P.; Sauane, M.; Sarkar, D.; Staudt, M.R.; Liu, S.J.; Taher, M.M.; Xiao, R.; Barral, P.; Lee, S.-G.; Wang, D.; Vozhilla, N.; Park, E.S.; Chatman, L.; Boukerche, H.; Ramesh, R.; Inoue, S.; Chada, S.; Li, R.; De Pass, A.L.; Mahasreshti, P.J.; Dmitriev, I.P.; Curiel, D.T.; Yacoub, A.; Grant, S.; Dent, P.; Senzer, N.; Nemunaitis, J.J.; Fisher, P.B. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int. J. Oncol., 2007, 31(5), 985-1007.
77. Eager, R.; Harle, L.; Nemunaitis, J. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert. Opin. Biol. Ther., 2008, 8(10), 1633-43.
78. Greco, A.; Di Benedetto, A; Howard, C.M.; Kelly, S.; Nande, R.; Dementieva, Y.; Miranda, M.; Brunetti, A.; Salvatore, M.; Claudio, L.; Sarkar, D.; Dent, P.; Curiel, D.T.; Fisher, P.B.; Claudio, P.P. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol. Ther., 2010, 18(2), 295-306.
79. Fisher P.B.; Babiss L.E.; Weinstein I.B.; Ginsberg H.S. Analysis of type 5 adenovirus transformation with a cloned rat embryo cell line (CREF). Proc. Natl. Acad. Sci. U.S.A., 1982, 79(11), 3527-31.
80. Su, Z.Z.; Austin, V.N.; Zimmer, S.G.; Fisher, P.B. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-rastransformed cloned rat embryo fibroblast cells. Oncogene, 1993, 8(5), 1211-9.
81. Su, Z.Z.; Lin, J.; Shen, R.; Fisher, P.E.; Goldstein, N.I.; Fisher, P.B. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc. Natl. Acad. Sci. U.S.A., 1996, 93(14), 7252-7.
82. Emdad, L.; Lee, S.G.; Su, Z.Z.; Jeon, H.Y.; Boukerche, H.; Sarkar, D.; Fisher, P.B. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc. Natl. Acad. Sci. U.S.A., 2009, 106(50), 21300-5.
83. Su, Z.; Shi, Y.; Friedman, R.; Qiao, L.; McKinstry, R.; Hinman, D.; Dent, P.; Fisher, P.B. PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells. Nucleic. Acids. Res., 2001, 29(8), 1661-71.
84. Su, Z.Z.,; Lee, S.G.; Emdad, L.; Lebdeva, I.V.; Gupta, P.; Valerie, K.; Sarkar, D.; Fisher, P.B. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc. Natl. Acad. Sci. U.S.A., 2008, 105(52), 20906-11.
85. Dash, R.; Richards, J.E.; Su, Z.Z.; Bhutia, S.K.; Azab, B.; Rahmani, M.; Dasmahapatra, G.; Yacoub, A.; Dent, P.; Dmitriev, I.P.; Curiel, D.T.; Grant, S.; Pellecchia, M.; Reed, J.C.; Sarkar, D.; Fisher, P.B. Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer. Res., 2010, 70(12), 5034-45.
86. Bhutia, S.K.; Dash, R.; Das, S.K.; Azab, B.; Su, Z.Z.; Lee, S.G.; Grant, S.; Yacoub, A.; Dent, P.; Curiel, D.T.; Sarkar, D.; Fisher, P.B. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer. Res., 2010, 70(9), 3667-76.